Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen.

Advocates call on Indian Minister of Health to discontinue and phase out the drug donations of bedaquiline offered by Johnson & Johnson.

Advocates call for minimizing the use of injectable agents and scaling up universal drug susceptibility testing.

Advocates call for removal of regulatory barriers, which contributed to the ongoing national stock out of GeneXpert MTB/RIF cartridges.

Advocates request that bedaquiline become part of the standard treatment regimen for drug-resistant TB in India.

Advocates call on Indian Prime Minister to personally attend the UN High-Level Meeting on TB and lead the country’s national delegation.

Advocates call on WHO leadership to ensure rapid development of clear, consolidated guidelines for the diagnosis and treatment of TB.

TB advocates urge the Commissioner to make a public statement on World TB Day, encouraging EU member states to attend the UN High-Level Meeting on TB, at the highest level.

Advocates appeal to the Prime Minister of India to issue a government use compulsory license for bedaquiline and delamanid to encourage generic competition.

TB CAB issues a position statement on the use of bedaquiline as part of the preferred regimen for MDR-TB.